Introduction of Anti-fibrotics Treatment in Combined Fibrosis and Pneumoconiosis and Prerequisites for Field Application

20 Nov 2026 11:15 11:30
Jun-Pyo Myong Speaker Republic of Korea
Background: Pneumoconiosis may progress as progressive pulmonary fibrosis (PPF), yet evidence for nintedanib in this population is limited. We describe six treated patients and barriers to access under Korea's workers' compensation system. Methods: We retrospectively reviewed six patients with pneumoconiosis or asbestosis who initiated nintedanib at a tertiary hospital between January 2025 and June 2026. Serial forced vital capacity (FVC), high-resolution computed tomography (HRCT), respiratory symptoms, and serum KL-6 were assessed. Results: All patients were men aged 64–88 years; five had dust-related pneumoconiosis and one had environmental asbestosis. Each showed at least two indicators of progression: FVC decline, radiological worsening, or worsening symptoms. Before treatment, five patients had relative FVC declines of 10.7–22.6%; one had gradual long-term decline with HRCT progression. After initiation, three reported symptomatic improvement. Of four patients with follow-up spirometry, two had relatively stable FVC and two had further declines. KL-6 decreased in two patients (1,191 to 869 U/mL; 546 to 451 U/mL). Post-treatment spirometry was unavailable for two patients. Two aftercare patients required case-by-case review for reimbursement. Conclusions: Nintedanib use was accompanied by symptomatic improvement or FVC stabilization in some patients with pneumoconiosis-associated PPF. Small sample size, limited follow-up, and lack of controls prevent causal inference. Reimbursement criteria for pneumoconiosis aftercare warrant revision to improve access to antifibrotic therapy.